
In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.
Martin Gouldstone, Chief Business Officer of Life Sciences, Sensyne, updates us on the status of AI in data used for clinical research, the difference between ethical AI vs. AI, and what Sensyne is trying to achieve in this space.






